High-dose non-sedating antihistamines are used insufficiently in chronic urticaria patients treated with omalizumab.
Hanne MadsenCharlotte Gotthard MortzCarsten Bindslev-JensenMette ReilevJesper HallasDaniel P HenriksenPublished in: Clinical and translational allergy (2021)
Omalizumab was usually administered before sufficient nsAH1 treatment was tried. In despite of the labelling that omalizumab should be co-administered with high dose nsAH1, this does not happen This may lead to substantial unnecessary costs.